Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Exact Sciences ( (EXAS) ) has shared an announcement.
On February 20, 2026, Exact Sciences stockholders held a special meeting to vote on proposals tied to the previously announced Agreement and Plan of Merger with Abbott Laboratories, under which Badger Merger Sub I, Inc. would merge with and into Exact, leaving Exact as a wholly owned subsidiary of Abbott. Shareholders representing 67.56% of outstanding shares as of the January 9, 2026 record date were present, and they overwhelmingly approved the merger agreement and the possible adjournment of the meeting to solicit additional proxies, while voting against, on an advisory basis, the proposed merger-related executive compensation, leaving completion of the transaction subject to remaining regulatory and customary closing conditions.
The most recent analyst rating on (EXAS) stock is a Hold with a $105.00 price target. To see the full list of analyst forecasts on Exact Sciences stock, see the EXAS Stock Forecast page.
Spark’s Take on EXAS Stock
According to Spark, TipRanks’ AI Analyst, EXAS is a Neutral.
The score is driven mainly by improving financial performance (notably strong recent cash generation) and a bullish technical trend, reinforced by an upbeat earnings call with raised guidance. These positives are tempered by continued net losses/leveraged balance sheet, weak traditional valuation signals (negative P/E and no dividend), and some deal-related legal uncertainty.
To see Spark’s full report on EXAS stock, click here.
More about Exact Sciences
Exact Sciences Corporation is a U.S.-based diagnostics company focused on cancer screening and detection tests, operating in the broader medical diagnostics and life sciences industry. Its products target early detection and prevention of cancer, positioning the company as a key player in oncology diagnostics and population-level screening programs.
Average Trading Volume: 3,911,190
Technical Sentiment Signal: Buy
Current Market Cap: $19.73B
For detailed information about EXAS stock, go to TipRanks’ Stock Analysis page.